Bioequivalence of Rebamipide Granules and Tablets in Healthy Adult Male Volunteers

Clinical Drug Investigation

Volumn 23, Issue 12, 2003, Pages 771-779

  Hasegawa, Setsuo ^a   Sekino, Hisakuni ^a   Matsuoka, Osamu ^a   Saito, Kazunori ^a   Sekino, Hisayuki ^a   Morikawa, Aki ^b   Uchida, Kaya ^b   Koike, Masami ^c   Azuma, Junichi ^d  

^a Sekino Clinical Pharmacology Clinic   (Japan)

^b SRL INC   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

REBAMIPIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FORMULATION; DRUG GRANULE; DRUG HALF LIFE; DYSPHAGIA; GASTRITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARAMETER; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ULCER; TABLET; TANDEM MASS SPECTROMETRY;

EID: 0347992813     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323120-00002     Document Type: Article

References (14)

1. Shiraki M, Yamasaki K, Ishiyama H, et al. Healing promoting effect of proamipide, a novel drug that increases gastric defense mechanisms, on acetic acid-induced gastric ulcers in the rat. Nippon Yakurigaku Zasshi 1988; 92: 389-95
2. Yamasaki K, Ishiyama H, Imaizumi T, et al. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jap J Pharmacol 1989; 49: 441-8
3. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 1993; 38: 1441-9
4. Ishiyama H, Yamasaki K, Kanbe T. Effect of proamipide (OPC-12759) on gastric mucus secretion in rats. Jpn Pharmacol Ther 1988; 16: 4103-9
5. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 1998; 43: 90S-8S
6. Watanabe S, Wang X, Hirose M, et al. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci 1998; 43: 107S-12S
7. Yoshikawa T, Naito Y, Nakamura S, et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneim Forsch/Drug Res 1993; 43: 1327-30
8. Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994; 35: 1375-8
9. Aihara M, Azuma A, Takizawa H, et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 1998; 43: 174S-80S
10. Arakawa T, Kobayashi K, Yoshikawa T, et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998; 43: 5S-13S
11. Arakawa T, Kobayashi K. Quality of ulcer healing: a new concept to rank healed peptic ulcers. Gastroenterol Jpn 1993; 28: 158-62
12. Arakawa T, Nebiki H, Higuchi K, et al. Rebamipide, a gastroprotective drug, improves quality of healing and decreases recurrence of gastric ulcer without affecting Helicobacter pylori status [abstract]. Gastrointest Endosc 1997; 45: AB87
13. Partially revised guidelines for bioequivalence studies of generic drugs [Pharmaceutical Affairs Bureau Notification No. 786]: Management Director, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan, 2001 May 31
14. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991; 29: 1-8